The Role of Sodium-Glucose cotransporter 2 inhibitors on Peripheral Nerves and Skeletal Muscle Function in Type 2 Diabetes
DOI:
https://doi.org/10.15605/jafes.041.02.6193Keywords:
diabetes, neuromuscular complications, peripheral nerves, SGLT2 inhibitors, skeletal musclesAbstract
Introduction. Diabetes is one of the four main non-communicable diseases in Sri Lanka with prevalence of 26%. SGLT2 inhibitors, primarily used for glycaemic control in type 2 diabetes, have recently garnered attention for their potential effects on neuromuscular function. The primary objective of this scoping review was to map the existing literature to determine the extent, range and nature of published evidence on the effects of SGLT2 inhibitors on peripheral nerve morphology, electrophysiology and skeletal muscle function and metabolic kinetics.
Methodology. Guided by the PRISMA extension for Scoping Reviews (PRISMA-ScR), an electronic search was executed across PubMed, ScienceDirect and Google Scholar for literature published from 2010 onwards. Applying a strict Population-Concept-Context (PCC) framework, two independent reviewers screened and analyzed studies evaluating human populations or corresponding animal models with T2DM (Population) undergoing SGLT2 inhibitor therapy (Concept), in relation to somatic/autonomic nerve conduction, nerve histology, muscle mass and metabolic processing (Context). Data extraction charted study characteristics, species, specific drug types, duration of effect and symptom relief versus electrophysiological outcomes.
Results. Thirty-two studies met the inclusion criteria with 16 evaluating peripheral nerves and 16 focusing on skeletal muscle kinetics. Evidence from animal models and human trials suggests potential improvements in peripheral nerve conduction velocity (NCV), epidermal nerve fiber density, skeletal muscle substrate flexibility, toward fatty acid and ketone oxidation, and mitochondrial structural dynamics. However, divergent and neutral functional outcomes, particularly in human muscle grip strength and short-term versus long-term clinical symptom recovery—were observed, highlighting critical knowledge gaps.
Conclusion. SGLT2 inhibitors demonstrate promising neuroprotective and myo-metabolic modulating properties via multiple pathways. However, the current literature is heavily geared towards animal models, with clear knowledge gaps on long-term effects on human function and symptom improvement. This review provides a mapped baseline to guide future targeted clinical trials.
Downloads
References
1. Randall D, Booth J, Wiles K, eds. Kumar and Clark's Clinical Medicine. 11th ed. Elsevier; 2025.
2. Centers for Disease Control and Prevention. About type 2 diabetes; 2025. Accessed February 13, 2025. https://www.cdc.gov/diabetes/about/about-type-2-diabetes.html
3. Akhtar S, Ali A, Asghar M, Hussain I, Sarwar A. Prevalence of type 2 diabetes and pre-diabetes in Sri Lanka: A systematic review and meta-analysis. BMJ Open. 2023;13(8):e068445. https://pubmed.ncbi.nlm.nih.gov/37640460 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10462943 https://doi.org/10.1136/bmjopen-2022-068445
4. International Diabetes Federation. IDF diabetes atlas reports; 2025. https://diabetesatlas.org/resources/idf-diabetes-atlas-2025/
5. Perry BD, Caldow MK, Brennan-Speranza TC, et al. Muscle atrophy in patients with type 2 diabetes mellitus: Roles of inflammatory pathways, physical activity and exercise. Exerc Immunol Rev. 2016;22:94-109. https://pubmed.ncbi.nlm.nih.gov/26859514 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5545118
6. Ishibashi FK, A.Tavakoli, M. Sodium glucose cotransporter-2 inhibitor protects against diabetic neuropathy and nephropathy in modestly controlled type 2 diabetes: Follow-up study. Front Endocrinol (Lausanne). 2022;13:864332. https://pubmed.ncbi.nlm.nih.gov/35784562 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9247156 https://doi.org/10.3389/fendo.2022.864332
7. Abdelkader NF, Elbaset MA, Moustafa PE, Ibrahim SM. Empagliflozin mitigates type 2 diabetes-associated peripheral neuropathy: A glucose-independent effect through AMPK signaling. Arch Pharm Res. 2022;45(7):475-93. https://pubmed.ncbi.nlm.nih.gov/35767208 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9325846 https://doi.org/10.1007/s12272-022-01391-5
8. El-Haggar SM, Hafez YM, El Sharkawy AM, Khalifa M. Effect of empagliflozin in peripheral diabetic neuropathy of patients with type 2 diabetes mellitus. Med Clin (Barc). 2024;163(2):53-61. https://pubmed.ncbi.nlm.nih.gov/38653618 https://doi.org/10.1016/j.medcli.2024.01.027
9. Volpe S, Vozza A, Lisco Gea. Sodium-glucose cotransporter 2 inhibitors improve body composition by increasing the skeletal muscle mass/fat mass ratio in patients with type 2 diabetes: A 52-week prospective real-life study. Nutrients. 2024;16(22):3841. https://pubmed.ncbi.nlm.nih.gov/39599627 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11597755 https://doi.org/10.3390/nu16223841
10. Kirk Ha. Robert K. Crane—Na(+)-glucose cotransporter to cure? Front Physiol. 0203;4:53. https://pubmed.ncbi.nlm.nih.gov/23525627 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3605518 https://doi.org/10.3389/fphys.2013.00053
11. Hediger MA, Coady MJ. Ikeda TS, Wright EM. Expression cloning and cDNA sequencing of the Na+/glucose co-transporter. Nature. 1987;330(6146):379-81. https://pubmed.ncbi.nlm.nih.gov/2446136 https://doi.org/10.1038/330379a0
12. Wright EM, Loo DDF, Hirayama BA. Biology of human sodium glucose transporters. Physiol Rev. 2011;91(2):733-94. https://pubmed.ncbi.nlm.nih.gov/21527736 https://doi.org/10.1152/physrev.00055.2009
13. Ghezzi CL, Loo DDF, Wright EM. Physiology of renal glucose handling via SGLT1, SGLT2 and GLUT2. Diabetologia. 2018;61(10):2087-97. https://pubmed.ncbi.nlm.nih.gov/30132032 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6133168 https://doi.org/10.1007/s00125-018-4656-5
14. Liu JJL, Lee T. DeFronzo RA. Why do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans? Diabetes. 2012;61(9):2199-204. https://pubmed.ncbi.nlm.nih.gov/22923645 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3425428 https://doi.org/10.2337/db12-0052
15. Barrett KE, Barman SM, Brooks HL, Yuan JX-J. Ganong's review of medical physiology, 26th ed. McGraw-Hill Education; 2019.
16. Hsia DSG, O. Cefalu, W. T. An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus. Curr Opin Endocrinol Diabetes Obes. 2017;24(1):73-9. https://pubmed.ncbi.nlm.nih.gov/27898586 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028052 https://doi.org/10.1097/MED.0000000000000311
17. DeFronzo RA, Hompesch, M., Kasichayanula, S. et al. Characterization of renal glucose reabsorption in response to dapagliflozin in healthy subjects and subjects with type 2 diabetes. Diabetes Care. 2013;36(10):3169-76. https://pubmed.ncbi.nlm.nih.gov/23735727 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3781504 https://doi.org/10.2337/dc13-0387
18. Nakamura SM, Miyachi Y, Shinjo A, et al Improved endurance capacity of diabetic mice during SGLT2 inhibition: Role of AICARP, an AMPK activator in the soleus. J Cachexia Sarcopenia Muscle. 2023;14(6):2866-81. https://pubmed.ncbi.nlm.nih.gov/37941098 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10751436 https://doi.org/10.1002/jcsm.13350
19. Gholami MC-F, N. Salehirad, Darbeheshti S, Motaghinejad M. Neuroprotective effects of sodium-glucose cotransporter-2 (SGLT2) inhibitors (Gliflozins) on Diabetes-induced neurodegeneration and neurotoxicity: A graphical review. Int J Prev Med. 2024;15:28. https://pubmed.ncbi.nlm.nih.gov/39239308 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11376549 https://doi.org/10.4103/ijpvm.ijpvm_5_23
20. Kandeel M. The outcomes of sodium-glucose co-transporter 2 inhibitors (SGLT2I) on diabetes-associated neuropathy: A systematic review and meta-analysis. Front Pharmacol. 2022;13:926717. https://pubmed.ncbi.nlm.nih.gov/35899123 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9310020 https://doi.org/10.3389/fphar.2022.926717
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Lakshani Dhananjanee Malwatta, Sampath Gunawardena, Vimukthi Rananjana Senanayake, Isuru Jayasanka Thabrew
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
The full license text is available at: http://creativecommons.org/licenses/by-nc/3.0/legalcode.
To request permission to translate, reproduce, download, or use articles or images for commercial reuse or business purposes from the Journal of the ASEAN Federation of Endocrine Societies (JAFES), kindly complete the Permission Request for Use of Copyrighted Material Form and email jafes@asia.com or jafes.editor@gmail.com.
A written agreement will be issued to the requester once permission has been granted.
